Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Vildagliptin in T2DM with CAD
NCT06313008Completed
- Sponsor
- Damanhour University
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Damanhour University. Primary endpoints: Left Ventricular Ejection Fraction at 6 months, Sortilin at 6 months and 1 more. Started Aug 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06313008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313008.